Humana Inc. (HUM) shares surged 5.11% in pre-market trading on Wednesday following the release of its impressive second-quarter 2025 financial results and upgraded full-year guidance. The health insurance giant demonstrated its ability to navigate the challenging healthcare landscape while delivering strong performance.

The company reported adjusted earnings per share (EPS) of $6.27 for Q2, surpassing analysts' expectations of $5.92. Revenue for the quarter reached $32.39 billion, also beating the estimated $31.89 billion. Notably, Humana's medical cost ratio came in at 89.7%, aligning with expectations and indicating effective management of healthcare costs.

Boosting investor confidence, Humana raised its full-year 2025 adjusted EPS guidance to approximately $17.00, up from the previous estimate of $16.25 and exceeding the consensus forecast of $16.38. The company also increased its revenue guidance to at least $128 billion, up from the previous range of $126-128 billion. This optimistic outlook, coupled with the strong Q2 performance, reflects Humana's confidence in its Medicare Advantage business and value-based care strategies, driving the pre-market stock surge.